☰

Suzanne M. Hector, Ph.D. - Publications

Affiliations: 
2005 State University of New York, Buffalo, Buffalo, NY, United States 
Area:
Pharmacology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Ryan D, Carberry S, Murphy ÁC, Lindner AU, Fay J, Hector S, McCawley N, Bacon O, Concannon CG, Kay EW, McNamara DA, Prehn JH. Calnexin, an ER-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer. Journal of Translational Medicine. 14: 196. PMID 27369741 DOI: 10.1186/S12967-016-0948-Z  0.318
2013 Lindner AU, Concannon CG, Boukes GJ, Cannon MD, Llambi F, Ryan D, Boland K, Kehoe J, McNamara DA, Murray F, Kay EW, Hector S, Green DR, Huber HJ, Prehn JH. Systems analysis of BCL2 protein family interactions establishes a model to predict responses to chemotherapy. Cancer Research. 73: 519-28. PMID 23329644 DOI: 10.1158/0008-5472.Can-12-2269  0.357
2012 Allen WL, Turkington RC, Stevenson L, Carson G, Coyle VM, Hector S, Dunne P, Van Schaeybroeck S, Longley DB, Johnston PG. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells. Molecular Cancer Therapeutics. 11: 1724-34. PMID 22665525 DOI: 10.1158/1535-7163.Mct-12-0207  0.382
2012 Hector S, Conlon S, Schmid J, Dicker P, Cummins RJ, Concannon CG, Johnston PG, Kay EW, Prehn JH. Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer. British Journal of Cancer. 106: 1499-1505. PMID 22481083 DOI: 10.1038/Bjc.2012.133  0.32
2012 Hector S, Rehm M, Schmid J, Kehoe J, McCawley N, Dicker P, Murray F, McNamara D, Kay EW, Concannon CG, Huber HJ, Prehn JH. Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy. Gut. 61: 725-33. PMID 22082587 DOI: 10.1136/Gutjnl-2011-300433  0.353
2012 McCawley N, Conlon S, Hector S, Cummins RJ, Dicker P, Johnston PG, Kay EW, McNamara DA, Prehn JH, Concannon CG. Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer. International Journal of Cancer. Journal International Du Cancer. 131: E494-500. PMID 21960357 DOI: 10.1002/Ijc.26468  0.337
2011 Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants. Cancer Chemotherapy and Pharmacology. 67: 401-14. PMID 20443003 DOI: 10.1007/S00280-010-1334-9  0.678
2010 Cannon MD, Concannon C, Hector S, Murray FE, Prehn JH. T1161 BH3 Mimetics Can Overcome Resistance to Chemotherapy in Colorectal Cancer Gastroenterology. 138. DOI: 10.1016/S0016-5085(10)62316-5  0.341
2009 Hector S, Prehn JHM. Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochimica Et Biophysica Acta. 1795: 117-129. PMID 19167459 DOI: 10.1016/J.Bbcan.2008.12.002  0.388
2008 Brun YF, Varma R, Hector SM, Pendyala L, Tummala R, Greco WR. Simultaneous modeling of concentration-effect and time-course patterns in gene expression data from microarrays. Cancer Genomics & Proteomics. 5: 43-53. PMID 18359979  0.548
2008 Hector S, Tummala R, Kisiel ND, Diegelman P, Vujcic S, Clark K, Fakih M, Kramer DL, Porter CW, Pendyala L. Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine. Cancer Chemotherapy and Pharmacology. 62: 517-27. PMID 17987291 DOI: 10.1007/S00280-007-0633-2  0.594
2007 Varma R, Hector S, Greco WR, Clark K, Hawthorn L, Porter C, Pendyala L. Platinum drug effects on the expression of genes in the polyamine pathway: Time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells Cancer Chemotherapy and Pharmacology. 59: 711-723. PMID 17021820 DOI: 10.1007/S00280-006-0325-3  0.641
2007 Hector S, Nava ME, Clark K, Murphy M, Pendyala L. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Cancer Letters. 245: 195-204. PMID 16516375 DOI: 10.1016/J.Canlet.2006.01.007  0.655
2005 Varma RR, Hector SM, Clark K, Greco WR, Hawthorn L, Pendyala L. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncology Reports. 14: 925-32. PMID 16142353 DOI: 10.3892/Or.14.4.925  0.654
2004 Bassett E, King NM, Bryant MF, Hector S, Pendyala L, Chaney SG, Cordeiro-Stone M. The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts. Cancer Research. 64: 6469-75. PMID 15374956 DOI: 10.1158/0008-5472.Can-04-1328  0.632
2004 Hector S, Porter CW, Kramer DL, Clark K, Prey J, Kisiel N, Diegelman P, Chen Y, Pendyala L. Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Molecular Cancer Therapeutics. 3: 813-22. PMID 15252142  0.638
2001 Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemotherapy and Pharmacology. 48: 398-406. PMID 11761458 DOI: 10.1007/S002800100363  0.665
Show low-probability matches.